Introduction

Percutaneous coronary intervention (PCI) is the cornerstone in the treatment of acute coronary syndrome (ACS). PCI is an evolving science and outcomes of which depend on characteristics of the individual patient, operator experience, availability of newer and more sophisticated hardware, improvement in our understanding of the science of atherosclerosis, etc. Since the first balloon angioplasty done by Dr Andreas Gruntzig in 1987, the art of PCI has changed a lot. Balloon angioplasty evolved into angioplasty with stenting and from bare-metal stents (BMS) to eluting drug stents (DES). DES is constantly changing from the type of drug being used to the amount of metal, the thickness of struts, platform design, etc. The stent classification system developed by Dr Sundeep Mishra helps in understanding the importance of newer stent with newer drugs [1]. Also, at the same time when stents are undergoing evolution, newer antiplatelet drugs with improved
efficacy and potency are being launched. American college of cardiology has put newer antiplatelets ticagrelor and prasugrel as first-line antiplatelet for patients undergoing PCI [2]. But the real-world data is quite different from trials data which are done in a controlled environment. Hence, came the concept of the registry to maintain real-world data which is usually free from pharmaceutical industry bias. Reviewing the registry helps us understand the real-world scenario and analysing it makes one more competent in dealing with patients in one’s locality.

Objectives: - To understand the age-wise & gender-wise distribution of patients; - To know the percentage prevalence of risk factors viz. diabetes mellitus, hypertension, smoking, tobacco chewing and alcohol intake among patients requiring PCI; - To know the prevalence of ST-elevation myocardial infarction (STEMI), non-ST elevation acute coronary syndrome (NSTE-ACS) & chronic stable angina (CSA) among patients who underwent PCI in real-world scenario; - To study the distribution of left ventricular ejection fraction (LVEF) among patients undergoing PCI; - To learn about the incidence of involvement of type of coronary artery and dimensions of coronary stents required for PCI; - To follow-up the cohort to calculate incidence of stent thrombosis, in-stent restenosis, other complications or deaths.

Methods

This is retrospective data analysis of 862 patients who underwent PCI from January 2016 to November 2017 at the department of cardiology in our institute under Mahatma Jyotiba Phule Jan Arogya Yojana (MJPJAY). This cohort was followed up in July 2018 with a mean duration of 604.4 ± 161.4 days.

Exclusion criteria: Patients who were in cardiogenic shock or required vasopressors or support ventilation before or at the time of PCI were excluded from the study.

Age-wise distribution is done as follows: A) teenage – defined as age between 13 years to 19 years; B) very young (3) – defined as age from 20 years to 35 years; C) young (4) – defined as age from 36 years to 55 years; D) peri-retirement – defined as age from 56 years to 64 years; and E) elderly [5], [6] – defined as age more than or equal to 65 years. Risk factors considered in the study were diabetes mellitus, hypertension, smoking, tobacco chewing or alcohol intake. Diabetes mellitus was defined in the study as per WHO guidelines, 2006 [7]. Hypertension was defined in the study as those patients who required pharmacologic therapy for hypertension as per the Eighth Joint National Committee (JNC 8) guidelines [8]. The individuals were classified as “chewing tobacco” if the patient or his/her relatives answered “yes” to the question of chewing tobacco. Similarly, individuals were categorised as “smokers” if the patient or his/her relatives answered, “yes” to the question of “smoking tobacco” [9].

Table 1: Summary of variables

| Variable             | Observation (n = 862) |
|----------------------|-----------------------|
| Male                 | 611 (70.86%)          |
| Female               | 251 (29.12%)          |
| Age                  |                       |
| Teenage (< 20)       | 1 (0.11%)             |
| Very Young (20 to ≤ 35) | 30 (3.48%)          |
| Young (35 to ≤ 55)   | 405 (46.98%)          |
| Peri-retirement (56 to 64) | 222 (25.75%)        |
| Elderly (≥ 65)       | 204 (23.66%)          |
| Diabetes             | 243 (28.19%)          |
| Hypertension         | 470 (54.52%)          |
| Tobacco chewer       | 158 (18.32%)          |
| Smoker               | 215 (24.52%)          |
| Alcoholic            | 111 (12.87%)          |
| STEMI                | 636 (73.76%)          |
| NSTE-ACS             | 153 (17.74%)          |
| CSA                  | 61 (7.07%)            |
| Thrombolysis         | 302 (34.84%)          |
| PAMI                 | 384 (44.03%)          |
| AWMI                 | 262 (29.11%)          |
| CTO                  | 47 (5.45%)            |
| SVD                  | 578 (67.05%)          |
| DVD                  | 262 (30.39%)          |
| TRO                  | 19 (2.20%)            |
| LVEF                 |                       |
| ≤ 30                 | 158 (18.32%)          |
| 30-45                | 239 (27.72%)          |
| 46-60                | 233 (27.03%)          |
| ≥ 60                 | 232 (26.91%)          |
| Follow-up means      | 654 (74.24)           |
| Local complication   | 9 (1.04%)             |
| Stent thrombosis     | 2 (0.23%)             |
| ISR                  | 11 (1.27%)            |

In the same way, alcohol intake was based on response either “yes” or “no” of the question to patients or their relatives when asked about alcohol drinking habit [10]. Acute coronary syndrome either STEMI [11] or NSTE-ACS [12] and chronic stable angina [13] were defined by the American College of Cardiology guidelines (ACC). Thrombolysis, whether done in our institute or patient, was thrombolysis at other centre and referred for further management was defined thrombolysis irrespective of thrombolytic agent used. Primary angioplasty in myocardial infarction (PAMI) was defined as when the patient presented within 6 hours of the onset of symptoms of ACS and was taken for PCI directly. STEMI was subclassified into anterior wall myocardial infarction (AWMI) or inferior wall myocardial infarction (IWMI) depending upon whether ST elevation is recorded in anterior chest lead or inferior leads respectively. Chronic total occlusion (CTO) of the coronary artery was defined as at least 3 months of total occlusion of coronary artery or infarct-related artery total occlusion when the primary event was recorded 3 months earlier plus the use of guide-wire for angioplasty with a tipping load of more than 4 gm. Single vessel disease (SVD) was the involvement of only one coronary artery with a significant lesion that requires intervention, while double vessel disease (DVD) was when two coronary arteries required intervention. Similarly, triple vessel disease (TVD) was defined when all the three left anterior descending (LAD), left circumflex (LCX) and right coronary artery (RCA) required stenting during PCI.
Stent details

The two stents that belong to second-generation DES used during this period for PCI at the department were as follows: 1) ProNOVA (Vascular concepts Ltd, India) and 2) Endeavor (Medtronic, United States of America).

Antiplatelet details

A loading dose of 300 mg of aspirin with 600 mg of clopidogrel was used in all patients anaalysed in the study and dual antiplatelet therapy with aspirin 75 mg and clopidogrel 75 mg once daily post PCI were prescribed. Stent thrombosis was defined as per timings and definition of academic research consortium [14]. Restenosis was defined in this study as more than 50% diameter stenosis in the patient who presents with either ACS or refractory symptoms despite optimal anti-anginal drugs. Local complications considered were pseudoaneurysm, hematoma, arterio-venous fistula. Deaths any reported during this period were classified into cardiac or non-cardiac based on verbal autopsy.

Data regarding all clinical and epidemiological variables were obtained from MJPJAY database of the hospital record. Follow-up of all patients that underwent PCI under MJPJAY scheme at our hospital excluding those mentioned in exclusion criteria was done in July 2018 at one point in time in a cross-sectional manner and any event in the past from the date of PCI was recorded as per protocol. Individual characteristic was expressed using the percentage of the total event.

Results

Out of 862 patients, 611 (70.88%) were male, and 251 (29.12%) were female. Patients’ age was uniformly distributed from 18 years of age to 85 years of age as shown in Table 2, with both median age and mean age being 55. Two hundred forty-three (28.19%) were diabetic and 470 (54.52%) were hypertensive. 158 (18.32%) patients were tobacco chewer, 215 (24.92%) were smokers and 111 (12.87%) were alcoholic. Six hundred thirty-six (73.78%) patients had STEMI, 153 (17.74%) had NSTE-ACS, 61 (7.07%) had CSA.

Table 2: Age-wise distribution

| Age             | Number | Percentage |
|-----------------|--------|------------|
| Teenage (< 30)  | 45     | 0.11       |
| Very Young (30 to ≤ 35) | 30     | 3.48       |
| Young (35 to ≤ 55) | 405    | 46.98      |
| Pre-retirement (56 to 64) | 222    | 25.75      |
| Elderly (≥ 65) | 204   | 23.66      |

Out of 636 patients with STEMI, 302 patients were thrombolysis (47.48%) before being referred to our centre and only 3 patients received PAMI. Also, out of STEMI patients, AWMI has diagnosed in 384 (60.37%) patients and IWMI in 262 (41.19%) patients.

Table 3: Distribution according to LVEF

| LVEF  | Number | Percentage |
|-------|--------|------------|
| <=30  | 158    | 18.32      |
| 30-45 | 239    | 27.72      |
| 46-60 | 233    | 27.03      |
| >=60  | 232    | 26.91      |

Table 3 shows the distribution of patients according to LVEF. Forty-seven (5.45%) patients were CTO, out which 5 (10.63%) attempts failed. As per this PCI registry, 578 (67.05%) were SVD, 262 (30.39%) were DVD and 19 (2.20%) were TVD. Out of SVD, 350 (60.55%) patients had LAD involvement and among DVD patients, LAD and RCA were most commonly involved in 107 (40.83%) patients. Five hundred seventy-seven times LAD PCI was done with average stent diameter of 2.97 mm and length of 25.68 mm, 186 times LCX PCI was done with average stent diameter of 2.86 mm and length of 22.84 mm and 327 times RCA PCI was done with average stent diameter of 3.20 mm and length of 25.86 mm.

On follow-up of mean 604.42 days (minimum 236 days, maximum 909 days), 9 (1.04%) had a local complication which included one event of pseudoaneurysm and one event of radial artery thrombosis both of which were treated conservatively. There were 2 (0.23%) episodes of subacute stent thrombosis and 11 (1.27%) patients had ISR.

Discussion

The PCI registry data described here comes from patients who underwent PCI under the government health scheme for poor at academic/university government hospital. Epidemiology of ischemic heart disease in India is of concern. According to the present PCI registry almost half of the population belonged to young age strata in contrast to United States National Cardiovascular Data Registry (US NCDR) database were mean age of PCI patients was 64.6 ± 12.1 and Japanese PCI registry where the mean age was 68.2 ± 9.8 [15]. The PURE study [16] describing epidemiological factors in the causation of cardiovascular diseases across different countries helps us understand these contrary findings in different countries. Diet, nutrition, the prevalence of diabetes & hypertension, access to healthcare facilities, funding for treatment of disease, etc. are the major determinants in making of this epidemiological picture. Also, as per the report of National Interventional Cardiology (NIC), 2011 for data on Indian coronary heart disease, 13.6% of patients were below 40 years of age [17]. Almost one
quarter i.e. 23.66% of patients undergoing PCI were elderly. This data shows a significant increase in the elderly population undergoing PCI for coronary artery disease but still, the young population is the majority affected. 70.88% of males are affected which is almost similar across the world statistics. More than half were hypertensive & more than one quarter were diabetic. Smoking, tobacco chewing and alcohol intake were involved as a risk factor in decreasing order. Three-fourth of patients undergoing PCI had STEMI which is way beyond described in US NCDR (14.44%), Japanese registry (23.01%) and NIC data (29.5%). Almost half of STEMI still undergo thrombolysis, and PAMI is occasional treatment received by the patient. Elective PCI for CSA is the least proportion of the population (~ 7%) while 22.3% population had CSA in NIC PIC registry, 31.69% in US NCDR and 50.59% in Japanese registry. Five percent CTO intervention is equit to 2.2% CTO in NIC registry, 3.2% US NCDR and 6.4% in Japanese registry. Patients undergoing PCI had LVEF as normal, mild, moderate and severe left ventricular dysfunction approximately one quarter in each level. LAD is the most common coronary artery that requires stenting and LAD with RCA is the most common double vessel disease encountered. Incidence of stent thrombosis and ISR is negligible to make out any inferences.

In conclusion, the epidemiological study of PCI data is of huge concern as it shows affection of young population predominately and gender inequality, suggesting primarily male disease. PCI is often sought in ACS and CSA is predominately treated medically. Thrombolysis remains the first treatment received by STEMI patients and PAMI is occasional. Single vessel disease is the most common form of coronary artery involvement with left anterior descending artery being the most commonly involved vessel. No mortality reported in approximately 2 years of follow-up with the negligible incidence of stent thrombosis or in-stent thrombosis shows the skill & knowledge of the operators of the centre and also presents real-world data for the second-generation stents and anti-platelet therapy used.

References

1. Mishra S. Are all stents equal-Need for scoring system to evaluate stents? 2016;589-591.
   https://doi.org/10.1016/j.jh.2016.08.012 PMid:27773393
   PMCid:PMC5078188

2. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart. Circulation. 2016 Sep 6;134(10):e123-55.
   https://doi.org/10.1161/CIR.0000000000000432

3. Li S, Zhang HW, Guo YL, Wu NQ, Zhu CG, Zhao X, Sun D, Gao XY, Gao Y, Zhang Y, Qing P. Familial hypercholesterolemia in very young myocardial infarction. Scientific reports. 2018; 8(1):8861.
   https://doi.org/10.1038/s41598-018-27248-w PMid:29892007
   PMCid:PMC5995844

4. Saldar B, Spatz ES, Dreyer RP, Beltrame JF, Lichtman JH, Spertus JA, Reynolds HR, Geda M, Bueno H, Dziura JD, Krumholz HM. Presentation, clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): results from the VIRGO Study. Journal of the American Heart Association. 2018; 7(13):e009174.
   https://doi.org/10.1161/JAHA.118.009174 PMcid:PMC6064896

5. Zabawa C, Cottenel J, Zeller M, Mercier G, Rodwin VG, Cottin Y, Quantin C. Thirty-day rehospitalizations among elderly patients with acute myocardial infarction: Impact of postdischarge ambulatory care. Medicine. 2018; 97(24):e11085.
   https://doi.org/10.1097/MD.0000000000011085 PMid:29901621
   PMCid:PMC6029393

6. Wennberg DE, Malenka DJ, Sengupta A, Lucas FL, Vaitkus PT, Quinton H, O’Rourke D, Robb JF, Kellett Jr MA, Shubrooks Jr SJ, Bradley WA. Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes. American heart journal. 1999; 137(4):639-45.
   https://doi.org/10.1016/S0002-8703(99)70216-4

7. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation.

8. James PA, Opari S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedgebe O, Smith SC. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507-20.
   https://doi.org/10.1001/jama.2013.284427 PMid:24352797

9. Rani M, Bonu S, Jha P, Nguyen SN, Jamjoum L. Tobacco use in India: prevalence and predictors of smoking and chewing in a national cross sectional household survey. Tobacco control. 2003; 12(4):e4. https://doi.org/10.1136/tc.12.4.e4 PMid:14660785
   PMCid:PMC1747786

10. Das SK, Balakrishnan V, Vasudevan DM. Alcohol: its health and social impact in India. National Medical Journal of India. 2006; 19(2):94.

11. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Grines CL, Jaffe AS, Komotars MC, Levine GN, 2014 AHA/ACC guideline for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. Circulation. 2008; 117(2):296-329.
   https://doi.org/10.1161/CIRCULATIONAHA.107.188209 PMid:18071078

12. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014; 64(24):e139-228.
   https://doi.org/10.1016/j.jacc.2014.08.013 PMid:25249586

13. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, 2016.
Douglas JS, Ferguson TB, Fihn SD, Fraker TD, Gardin JM, O’Rourke RA. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology. 2003; 41(1):159-68. https://doi.org/10.1016/S0735-1097(02)02848-6

14. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Vranckx P, McFadden E. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. https://doi.org/10.1161/CIRCULATIONAHA.106.685313 PMid:17470709

15. Kohsaka S, Miyata H, Ueda I, Masoudi FA, Peterson ED, Maekawa Y, Kawamura A, Fukuda K, Roe MT, Rumsfeld JS. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KICS). American heart journal. 2015; 170(6):1077-85. https://doi.org/10.1016/j.ahj.2015.09.017 PMid:26678628

16. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic non communicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009; 158:1-7. https://doi.org/10.1016/j.ahj.2009.04.019 PMid:19540385

17. Ramakrishnan S, Mishra S, Chakraborty R, Chandra KS, Mardikar HM. The report on the Indian coronary intervention data for the year 2011-National Interventional Council. Indian heart journal. 2013; 65(5):518-21. https://doi.org/10.1016/j.ihj.2013.08.009 PMid:24206874 PMCID:PMC3861090